Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/5346
Title: Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone
Authors: Bolaman, Z.
Köseoglu, M.
Ayyildiz, O.
Kadiköylü, G.
Sönmez, H.M.
Demir, S.
Müftuüoglu, E.
Keywords: Blastic phase
Chronic myelogenous leukemia
High dose methylprednisolone
5 aza 2' deoxycytidine
alpha interferon
azacitidine
carboplatin
cladribine
cytarabine
etoposide
fludarabine
granulocyte colony stimulating factor
hydroxyurea
imatinib
meprednisone
mitoxantrone
prednisolone
vincristine
adult
age distribution
article
bacteremia
blast cell crisis
bone marrow hypoplasia
cause of death
chronic myeloid leukemia
clinical article
clinical trial
conjunctivitis
controlled clinical trial
controlled study
diarrhea
dose response
drug megadose
drug tolerability
febrile neutropenia
female
fever
flushing
human
leukemia remission
leukopenia
liver dysfunction
lung toxicity
male
mucosa inflammation
nausea and vomiting
neurotoxicity
Philadelphia 1 chromosome
pneumonia
prognosis
rash
Streptococcus infection
survival time
validation process
Adult
Antineoplastic Combined Chemotherapy Protocols
Blast Crisis
Cytarabine
Female
Humans
Leukemia, Myeloid, Chronic
Male
Methylprednisolone
Middle Aged
Mitoxantrone
Remission Induction
Survival Analysis
Treatment Outcome
Abstract: Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days. The patients' mean age was 52 ± 10 (range 34-64) and Philadelphia chromosome was positive in all. Five patients (35%) achieved complete remission and four patients (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 ± 8.6 months (median 13) for all patients, 19.4 ± 4.0 months (median 19) for those achieving a complete remission, 12.50 ± 5.7 months (median 14) for patients with partial remission and 1.8 ± 1.8 months (median 2) for the unresponsive patients. Two of 5 unresponsive patients died early after the second course of remission induction. The treatment regimen was generally well tolerated. Marrow hypoplasia was observed in 9 (64%) patients and 7 (50%) had febrile episodes. Non-myelosupressive toxicity of the regimen was acceptable. Nausea and vomiting were observed in 8 (57%) patients and 3 (21%) patients developed flushing due to cytosine arabinoside. These results suggest that the regimen with mitoxantrone, cytosine arabinoside and high dose methylprednisolone in remission-induction of blastic phase chronic myelogenous leukemia may be a valid option that may also improve overall prognosis.
URI: https://hdl.handle.net/11499/5346
https://doi.org/10.1163/156855902760262763
ISSN: 0017-6559
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Nov 30, 2024

WEB OF SCIENCETM
Citations

1
checked on Dec 5, 2024

Page view(s)

40
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.